# Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer

> **NCT00786422** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 25 (actual)

## Conditions studied

- Venous Thrombosis
- Deep Vein Thrombosis

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)

## Key facts

- **NCT ID:** NCT00786422
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2011-05
- **Final completion:** 2011-06
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2015-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00786422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00786422, "Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00786422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*